17:00 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...
17:07 , Sep 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest inhibiting senescent cells could help treat age-related bone loss. In aged, transgenic mice expressing the senescence marker human CDKN2A , a tool compound that depletes CDKN2A-positive cells decreased the number...
07:00 , Mar 30, 2015 |  BioCentury  |  Emerging Company Profile

Effusion dissolution

Lung Therapeutics Inc. is developing therapies that prevent or resolve fibrosis to treat Orphan lung diseases. Lead product LTI-01 is a formulation of a fibrinolytic enzyme in preclinical development to prevent and clear loculated pleural...
08:00 , Feb 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Plasminogen activator inhibitor 1 (SERPINE1; PAI1)

Infectious disease INDICATION: Influenza virus Cell culture and mouse studies suggest SERPINE1 or SERPINE1 agonists could help treat influenza A viral infection. A high throughput microscopy screen in human lung cells engineered to express interferon...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

THR-18: Additional Phase IIa data

A double-blind, placebo-controlled, Ukrainian Phase IIa trial in 30 patients with acute ischemic stroke showed that THR-18 in combination with tissue plasminogen activator (tPA) met the primary safety endpoint. Specifically, no patients receiving THR-18 plus...
07:00 , Jul 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Cancer; thrombosis Plasminogen activator inhibitor 1 (SERPINE1; PAI1) In vitro and mouse studies suggest enhancing the interaction of PAI1 with the N-terminal region of prolactin...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Actin a2 smooth aorta muscle (ACTA2; a-SMA); smoothened (SMO); sonic hedgehog homolog (SHH) Studies in mice and patients suggest depleting tumor stroma and...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Other Plasminogen activator inhibitor 1 (SERPINE1; PAI1) Mouse studies suggest inhibiting PAI1 could prevent age-related tissue dysfunction. In a mouse model of premature aging, Pai1...
08:00 , Nov 21, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Computational models

This week in techniques Approach Summary Licensing status Publication and contact information Computational models Analysis of adverse events database to identify mechanisms underlying side effects In silico and mouse studies suggest analysis of adverse events...
08:00 , Nov 14, 2013 |  BC Innovations  |  Cover Story

Trends with benefits

The FDA set up its adverse event database decades ago to capture the side effects of marketed drugs, but a group from the Icahn School of Medicine at Mount Sinai has now exploited the millions...